Stephen E Haynesworth

US Patent:

7470538, Dec 30, 2008

Filed:

Jun 24, 2004

Appl. No.:

10/875643

Inventors:

Mary J. Laughlin - Shaker Heights OH, US
Stephen Haynesworth - Beachwood OH, US
Vincent Pompili - Hudson OH, US

Assignee:

Case Western Reserve University - Cleveland OH

International Classification:

C12N 5/00

US Classification:

435325, 424 937

Abstract:

The invention provides, among other things, methods for treating an ischemic tissue in a subject in need thereof. The invention further provides methods for increasing the blood flow to an ischemic tissue in a subject in need thereof, such as to ischemic myocardium. The invention further provides cell-based formulations and related kits.

US Patent:

20040258670, Dec 23, 2004

Filed:

Dec 5, 2003

Appl. No.:

10/730549

Inventors:

Mary Laughlin - Shaker Heights OH, US
Stephen Haynesworth - Beachwood OH, US
Vincent Pompili - Hudson OH, US

Assignee:

Case Western Reserve University - Cleveland OH

International Classification:

A61K048/00
C12N005/08

US Classification:

424/093210, 435/372000

Abstract:

The invention provides, among other things, methods for treating an ischemic tissue in a subject in need thereof. The invention further provides methods for increasing the blood flow to an ischemic tissue in a subject in need thereof, such as to ischemic myocardium. The invention further provides cell-based formulations.

US Patent:

55916252, Jan 7, 1997

Filed:

Nov 24, 1993

Appl. No.:

8/158000

Inventors:

Stanton L. Gerson - Pepper Pike OH
Arnold I. Caplan - Cleveland Heights OH
Stephen E. Haynesworth - Cleveland Heights OH

Assignee:

Case Western Reserve University - Cleveland OH

International Classification:

C12N 510
C12N 508
C12N 1586
A61K 4800

US Classification:

4352402

Abstract:

Genetically engineered human stem cells that carry within them genes of interest particularly for the expression of physiologically or pharmacologically active proteins or for use in gene therapy. In addition to correction of genetic disorders, is the ability to introduce, in a targeted manner, additional copies of essential genes to allow expression in proliferating, nondifferentiating cells of certain gene products. These genes can be, for example, hormones matrix proteins, cytokines, adhesion molecules, detoxification enzymes and "rebuilding" proteins important in tissue repair.

US Patent:

54863597, Jan 23, 1996

Filed:

Feb 8, 1994

Appl. No.:

8/193262

Inventors:

Arnold I. Caplan - Cleveland Heights OH
Stephen E. Haynesworth - Cleveland Heights OH

Assignee:

Osiris Therapeutics, Inc. - Cleveland OH

International Classification:

A61K 3512
C12N 500
C12N 508

US Classification:

424 937

Abstract:

Isolated human mesenchymal stem cells which can differentiate into more than one tissue type (e. g. bone, cartilage, muscle or marrow stroma), a method for isolating, purifying, and culturally expanding human mesenchymal stem cells (i. e. "mesenchymal stem cells" or "hMSCs"), and characterization of and uses, particularly research reagent, diagnostic and therapeutic uses for such cells. The stem cells can be culture expanded without differentiating. Monoclonal antibodies specific for human mesenchymal stem cells and the monoclonal hybridoma cell lines (ATCC nos. 10743-10745) that synthesize and secrete these monospecific antibodies, and uses of the monoclonal antibodies for diagnostic and/or therapeutic purposes.

US Patent:

52269140, Jul 13, 1993

Filed:

Nov 16, 1990

Appl. No.:

7/614912

Inventors:

Arnold I. Caplan - Cleveland Heights OH
Stephen E. Haynesworth - Cleveland Heights OH

International Classification:

A61F 228
A61K 3512

US Classification:

623 16

Abstract:

The present invention is directed to various processes and devices for utilizing isolated and culturally expanded marrow-derived mesenchymal cells (i. e. mesenchymal stem cells) for treating skeletal and other connective tissue disorders.

US Patent:

58375392, Nov 17, 1998

Filed:

Jun 2, 1995

Appl. No.:

8/458494

Inventors:

Arnold I. Caplan - Cleveland Heights OH
Stephen E. Haynesworth - Cleveland Heights OH

Assignee:

Osiris Therapeutics, Inc. - Baltimore MD

International Classification:

C12N 520
C07K 1628

US Classification:

435332

Abstract:

The invention relates to isolated human mesenchymal stem cells, a method for isolating, purifying, and culturally expanding human mesenchymal stem cells (i. e. mesenchymal stem cells or "MSCs"), and characterization of (including by cytokine expression profiling) and uses, particularly research reagent, diagnostic and therapeutic uses for such cells. The stem cells can be culture expanded without differentiating. Further disclosed are monoclonal antibodies specific for human mesenchymal stem cells and the monoclonal hybridoma cell lines (ATCC nos. 10743-10745) that synthesize and secrete these monospecific antibodies, and uses of the monoclonal antibodies for diagnostic and/or therapeutic purposes.

US Patent:

60106964, Jan 4, 2000

Filed:

Mar 25, 1998

Appl. No.:

9/047950

Inventors:

Arnold I. Caplan - Cleveland Heights OH
Stephen E. Haynesworth - Cleveland Heights OH
Stanton L. Gerson - Pepper Pike OH
Hillard M. Lazarus - Shaker Heights OH

Assignee:

Osiris Therapeutics, Inc. - Baltimore MD

International Classification:

C12N 500
A61K 3528
A61F 1300

US Classification:

424 937

Abstract:

Method and preparations for enhancing hematopoietic progenitor cell engraftment in an individual by administering (i) a culturally expanded mesenchymal stem cell preparation and (ii) hematopoietic progenitor cells. The mesenchymal stem cells are administered in an amount effective to promote engraftment of the hematopoietic progenitor cells.

US Patent:

59422254, Aug 24, 1999

Filed:

Jul 23, 1997

Appl. No.:

8/899414

Inventors:

Scott P. Bruder - Owings Mills MD
Arnold I. Caplan - Cleveland Heights OH
Stephen E. Haynesworth - Cleveland Heights OH

Assignee:

Case Western Reserve University - Cleveland OH
Osiris Therapeutics, Inc. - Baltimore MD

International Classification:

C12N 500

US Classification:

424 937

Abstract:

Methods for in vitro or ex vivo lineage directed induction of isolated, culture expanded human mesenchymal stem cells comprising contacting the mesenchymal stem cells with a bioactive factor effective to induce differentiation thereof into a lineage of choice as well as such compositions including isolated culture expanded human mesenchymal stem cells and bioactive factors effective to induce directed lineage induction are disclosed. Further disclosed is this method which also includes introducing such culturally expanded lineage-induced mesenchymal stem cells into a host from which they have originated for purposes of mesenchymal tissue regeneration or repair.